Merck KGaA Crescita futura

Future criteri di controllo 1/6

Merck KGaA prevede che gli utili e i ricavi cresceranno rispettivamente di 10.7% e 4.2% all'anno. Si prevede che l'EPS crescerà di 11% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.9% in 3 anni.

Informazioni chiave

10.7%

Tasso di crescita degli utili

11.0%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.9%
Tasso di crescita dei ricavi	4.2%
Rendimento futuro del capitale proprio	12.9%
Copertura analitica	Good
Ultimo aggiornamento	18 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

OTCPK:MKGA.F - Stime future degli analisti e dati finanziari passati (EUR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	23,045	3,702	3,733	5,255	13
12/31/2025	22,074	3,395	3,304	5,006	14
12/31/2024	21,163	2,945	3,011	4,597	14
9/30/2024	20,963	2,696	2,160	4,408	N/A
6/30/2024	20,870	2,626	2,052	4,205	N/A
3/31/2024	20,820	2,722	1,961	3,966	N/A
12/31/2023	20,993	2,824	1,897	3,784	N/A
9/30/2023	21,428	2,893	1,912	3,746	N/A
6/30/2023	22,061	3,078	2,198	4,042	N/A
3/31/2023	22,327	3,242	2,334	4,272	N/A
12/31/2022	22,232	3,326	2,491	4,259	N/A
9/30/2022	21,785	3,473	2,788	4,289	N/A
6/30/2022	20,952	3,311	2,658	4,204	N/A
3/31/2022	20,254	3,188	2,734	4,240	N/A
12/31/2021	19,687	3,055	3,234	4,616	N/A
9/30/2021	19,072	2,689	3,125	4,859	N/A
6/30/2021	18,546	2,733	3,073	4,562	N/A
3/31/2021	17,795	2,278	2,702	4,177	N/A
12/31/2020	17,534	1,987	2,002	3,477	N/A
9/30/2020	17,317	1,884	1,684	2,879	N/A
6/30/2020	16,924	1,419	1,498	2,640	N/A
3/31/2020	16,776	1,549	1,729	2,879	N/A
12/31/2019	16,152	1,292	1,858	2,856	N/A
9/30/2019	15,658	1,139	1,967	2,906	N/A
6/30/2019	15,354	1,118	1,751	2,706	N/A
3/31/2019	15,096	938	1,425	2,332	N/A
12/31/2018	14,836	1,071	1,270	2,219	N/A
9/30/2018	14,597	1,921	1,031	2,120	N/A
6/30/2018	14,364	2,218	N/A	2,147	N/A
3/31/2018	14,346	2,389	N/A	2,299	N/A
12/31/2017	14,517	2,548	N/A	2,696	N/A
9/30/2017	14,699	1,787	N/A	2,842	N/A
6/30/2017	14,906	1,628	N/A	3,152	N/A
3/31/2017	15,016	1,529	N/A	2,943	N/A
12/31/2016	15,024	1,629	N/A	2,518	N/A
9/30/2016	14,658	1,480	N/A	2,449	N/A
6/30/2016	14,054	1,387	N/A	2,253	N/A
3/31/2016	13,469	1,418	N/A	2,268	N/A
12/31/2015	12,845	1,109	N/A	2,195	N/A
9/30/2015	12,380	1,269	N/A	2,618	N/A
6/30/2015	12,180	1,154	N/A	2,472	N/A
3/31/2015	11,776	1,114	N/A	2,576	N/A
12/31/2014	11,363	1,157	N/A	2,706	N/A
9/30/2014	11,106	1,158	N/A	2,005	N/A
6/30/2014	10,937	1,249	N/A	2,105	N/A
3/31/2014	10,963	1,261	N/A	2,119	N/A
12/31/2013	11,095	1,202	N/A	2,226	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di MKGA.F ( 10.7% all'anno) è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che gli utili di MKGA.F ( 10.7% all'anno) cresceranno più lentamente rispetto al mercato US ( 15.3% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di MKGA.F cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di MKGA.F ( 4.2% all'anno) crescerà più lentamente rispetto al mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MKGA.F ( 4.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di MKGA.F sarà basso tra 3 anni ( 12.9 %).

Merck KGaA Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Merck Launches New, High-Purity Synthetic Cholesterol Product

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines

Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

Day One Biopharmaceuticals Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Mek Inhibitor Pimasertib

MERCK Kommanditgesellschaft auf Aktien to Report Q3, 2021 Results on Nov 11, 2021

4D Pharma plc Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with Bavencio for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2020 Results on Mar 04, 2021

MERCK Kommanditgesellschaft auf Aktien to Discontinue Bintrafusp Alfa Clinical Trial (INTR@PID Lung 037)

Merck KGaA, Darmstadt, Germany to Deploy Insilico Medicine's Chemistry42 AI Platform for Generative Chemistry

Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics

Iktos Announces Additional Collaboration with Merck KGaA, Darmstadt, Germany in AI for New Drug Design

Merck KGaA Announces Executive Changes

LycoRed Natural Products Industries Ltd. acquired Nutriblend Ltd. from Merck KGaA.

Rakuten Medical Enters into Partnership with Merck

MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2021 Results on Aug 05, 2021

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita